

January 28, 2022

To,

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
(THYROCARE)

BSE Limited
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400 001
(539871)

Dear Sir/Madam,

Sub: Outcome of Board Meeting- 28-01-2022- Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that the Board of Directors of the Company, at their meeting held today,

Approved the following Special Purpose Interim Consolidated financial statements - For the period 1st April to 30th November 2021 and for the stub period 2nd September to 30th November 2021.

Approved the Restated financial statements for the stub period 2nd September to 30th November 2021.

These statements would be shared with API Holdings Limited, who are our step-up holding company, for inclusion in their consolidated financial statements, to be incorporated in the proposed RHP for their ensuing IPO, in accordance with the provisions of SEBI (ICDR) Regulations, 2018.

These statements, which may contain details that might be considered as unpublished price sensitive information, will be used only for the purpose for which it is meant and shall not be published or shared by API Holdings Limited with any other third party entity or individual, unless it is intended for inclusion in their Consolidated financial statements, in line with the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015..

2. The Board has appointed Mr. Sachin Salvi, presently working as Senior Vice-President-Finance, as Chief Financial Officer of the Company effective from today, 28th January 2022.

The meeting commenced at 11.30 AM and concluded at 01.45 PM

Yours Faithfully,

For **Thyrocare Technologies Limited**,



Ramjee Dorai
Company Secretary and Compliance Officer



Thyrocare Technologies Limited